New Charité spin-off aims to detect acute kidney injury ten times faster
“Nephrolytix’s aim is to set a new gold standard for kidney function diagnostics that will help millions of patients”
acute kidney injury (AKI) is commonly seen in hospitals. It entails the rapid deterioration of kidney function, a high disease burden, and leads in some cases to death. The team at Nephrolytix GmbH, a new spin-off of Charité – Universitätsmedizin Berlin, has developed a process with the potential to reduce the time it takes to detect AKI – currently 48 to 72 hours – by 90 percent. The endeavor was funded by Charité BIH Innovation, the joint technology transfer office of Charité and the Berlin Institute of Health at Charité (BIH), as part of the BIH Digital Health Accelerator program.
Symbolic image
pixabay.com/Unsplash
To detect AKI, clinicians measure a series of biomarkers. The results take 48 to 72 hours – a time lag that significantly delays treatment. Now the team of researchers at Nephrolytix, led by Prof. Markus van der Giet of Charité’s Department of Nephrology and Medical Intensive Care, has developed a procedure that can diagnose AKI within the first seven hours – less than a tenth of the standard time. It involves using a database with data from previously recorded cases of AKI, a protocol for measuring contrast agents, and software designed specially by the team. The procedure can be easily integrated anywhere into modern clinical workflows. And considering the low costs involved, it promises a substantial improvement in patient outcomes and the efficiency of the health care system generally.
“Our innovation grew out of a clinical need that we nephrologists experience every day at Charité. It is based on longstanding research whose results we were able to carry over into the Charité spin-off Nephrolytix. This research transfer was only possible thanks to the BIH and its Digital Health Accelerator program,” explains Prof. Markus van der Giet, inventor of the technology and chief medical officer and co-founder of Nephrolytix.
Bartosz Reinhold, CEO and co-founder of Nephrolytix, adds, “Nephrolytix’s aim is to set a new gold standard for kidney function diagnostics that will help millions of patients. To achieve this aim, we are developing products that future doctors around the world will be able to use. Part of Nephrolytix’s goal is thus to enable this scale of impact.”
An example of medical translation from clinical research to patient care
Nephrolytix GmbH is the seventh spin-off produced by the BIH Digital Health Accelerator (DHA) program. Prof. Christopher Baum, Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité, comments: “It is a joy to watch the successful develpoment of our DHA program. On the one hand, it undescores the high potential for medical translation from Charité and the BIH, especially in the realm of digital medicine. On the other hand, it proves the relevance and effectiveness of internal professional funding efforts, such as the BIH DHA and SPARK-BIH programs, for translating new medical innovations into practical applications. In this way, the BIH is fulfilling its mission to ‘turn research into health,’ pursuing a mandate entrusted to it by the German federal governemnt, and making a contribution to society.”
Thomas Gazlig, head of Charité BIH Innovation, where the BIH DHA program is located, adds: “Now the construction of a pipeline for development and transfer projects is visibly bearing fruit. We are working as hard as we can to strengthen this pipeline in the form of our two funding programs.” For in his view, despite the potential for economic success and for reinvesting a significant portion of profits in new development projects, subsidies such as the current special funding provided by the federal government would still be necessary.
Tim Huse, head of the BIH DHA program, adds: “This seventh spin-off from our program represents yet another transfer success story. We would like to share with other university hospitals the approach we have developed and the experience we have gained in order to support the development and success of innovative digital health products and companies throughout Germany.” Such an endeavor, he notes, would require interest on the part of the institutions and the corresponding political will.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
